In this week’s video, Dr. Brian G.M. Durie explains how the ARROW study demonstrated efficacy and low toxicity for weekly dosing of carfilzomib. BOTTOM LINE: Ensure your doctor is aware of the ARROW study in order to consider once-weekly dosing of carfilzomib. |
|||
Have a question? Submit it to AskDrDurie@myeloma.org |
|||
IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org! |